Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 10.


Cahn, Avivit, Wiviott, Stephen D, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Leiter, Lawrence A, Bhatt, Deepak L
et al (show 8 more authors) (2020) Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58. DIABETES OBESITY & METABOLISM.


Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, KyungAh, Goodrich, Erica L, Furtado, Remo HM, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit
et al (show 5 more authors) (2019) Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation.


Raz, Itamar, Mosenzon, Ofri, Bonaca, Marc P, Cahn, Avivit, Kato, Eri T, Silverman, Michael G, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404
et al (show 5 more authors) (2018) DECLARE-TIMI 58: Participants' baseline characteristics. DIABETES OBESITY & METABOLISM, 20 (5). 1102 - 1110.


Bonaca, Marc P, Wiviott, Stephen D, Zelniker, Thomas A, Mosenzon, Ofri, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Goodrich, Erica L, De Mendonca Furtado, Remo Holanda, Wilding, John PH ORCID: 0000-0003-2839-8404
et al (show 8 more authors) (2020) Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 142 (8). 734 - 747.


Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 13 more authors) (2019) Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. CIRCULATION, 139 (22). 2528 - 2536.


Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo JL, Zelniker, Thomas A, Dwyer, Jamie P
et al (show 11 more authors) (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (8). 606 - 617.


Cahn, Avivit, Mosenzon, Ofri, Wiviott, Stephen D, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K
et al (show 7 more authors) (2020) Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. DIABETES CARE, 43 (2). 468 - 475.


Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM
et al (show 5 more authors) (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. LANCET, 393 (10166). 31 - 39.


Cahn, Avivit, Raz, Itamar, Bonaca, Marc, Mosenzon, Ofri, Murphy, Sabina A, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Bhatt, Deepak L, McGuire, Darren K
et al (show 9 more authors) (2020) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. DIABETES OBESITY & METABOLISM, 22 (8). 1357 - 1368.


Wiviott, Stephen D, Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 6 more authors) (2018) The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. AMERICAN HEART JOURNAL, 200. 83 - 89.

This list was generated on Sun Nov 15 00:49:25 2020 GMT.